Smart nanocarriers for enzyme-activated prodrug therapy

References

• A.D. Ross, G. Varghese, B. Oporto, F.J. Carmichael, Y. Israel, Effect of propylthiouracil treatment on NADPH-cytochrome P450 reductase levels, oxygen consumption and hydroxyl radical formation in liver microsomes from rats fed ethanol or acetone chronically, Biochem. Pharmacol. 49 (1995) 979–989. doi: 10.1016/0006-2952.(95)00007-m.
   Google Scholar
• P.-A. Burnouf, Y.-L. Leu, Y.-C. Su, K. Wu, W.-C. Lin, S.R. Roffler, Reversible glycosidic switch for secure delivery of molecular nanocargos, Nat. Commun. 9 (2018) 1843. doi: 10.1038/s41467-018-04225-5.
   Google Scholar
• K.J. Isaacson, M. Martin Jensen, N.B. Subrahmanyam, H. Ghandehari, Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression, J. Control. Release Off. J. Control. Release Soc. 259 (2017) 62–75. doi: 10.1016/j.jconrel.2017.01.034.
   Google Scholar
• M. Hosokawa, Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs, Mol. Basel Switz. 13 (2008) 412–431. doi: 10.3390/molecules13020412.
   Google Scholar
• S. Sheikh, D. Ernst, A. Keating, Prodrugs and prodrug-activated systems in gene therapy, Mol. Ther. 29 (2021) 1716–1728. doi: 10.1016/j.ymthe.2021.04.006.
   Google Scholar
• M. De La Fuente, L. Lombardero, A. Gómez-González, C. Solari, I. Angulo-Barturen, A. Acera, E. Vecino, E. Astigarraga, G. Barreda-Gómez, Enzyme Therapy: Current Challenges and Future Perspectives, Int. J. Mol. Sci. 22 (2021) 9181. doi: 10.3390/ijms22179181.
   Google Scholar
• K.V. Nemani, R.C. Ennis, K.E. Griswold, B. Gimi, Magnetic nanoparticle hyperthermia induced cytosine deaminase expression in microencapsulated E. coli for enzyme–prodrug therapy, J. Biotechnol. 203 (2015) 32–40. doi: 10.1016/j.jbiotec.2015.03.008.
   Google Scholar
• K. Bagshawe, C. Springer, F. Searle, P. Antoniw, S. Sharma, R. Melton, R. Sherwood, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58 (1988) 700–703. doi: 10.1038/bjc.1988.293.
   Google Scholar
• E. Appel, A. Rabinkov, M. Neeman, F. Kohen, D. Mirelman, Conjugates of daidzein-alliinase as a targeted pro-drug enzyme system against ovarian carcinoma, J. Drug Target. 19 (2011) 326–335. doi: 10.3109/1061186X.2010.504265.
   Google Scholar
• N.P. Minton, M.L. Mauchline, M.J. Lemmon, J.K. Brehm, M. Fox, N.P. Michael, A. Giaccia, J.M. Brown, Chemotherapeutic tumour targeting using clostridial spores, FEMS Microbiol. Rev. 17 (1995) 357–364. doi: 10.1111/j.1574-6976.1995.tb00219.x.
   Google Scholar
• S.A. Rosenberg, P. Aebersold, K. Cornetta, A. Kasid, R.A. Morgan, R. Moen, E.M. Karson, M.T. Lotze, J.C. Yang, S.L. Topalian, M.J. Merino, K. Culver, A.D. Miller, R.M. Blaese, W.F. Anderson, Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction, N. Engl. J. Med. 323 (1990) 570–578. doi: 10.1056/NEJM199008303230904.
   Google Scholar
• V.V. Gwenin, C.D. Gwenin, M. Kalaji, Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy, Langmuir ACS J. Surf. Colloids 27 (2011) 14300–14307. doi: 10.1021/la202951p.
   Google Scholar
• R. Dhankhar, V. Gupta, S. Kumar, R.K. Kapoor, P. Gulati, Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment, Appl. Microbiol. Biotechnol. 104 (2020) 2857–2869. doi: 10.1007/s00253-020-10432-2.
   Google Scholar
• R. Mooney, A. Abdul Majid, J. Batalla, A.J. Annala, K.S. Aboody, Cell-mediated enzyme prodrug cancer therapies, Adv. Drug Deliv. Rev. 118 (2017) 35–51. doi: 10.1016/j.addr.2017.09.003.
   Google Scholar
• P. Lehouritis, C. Springer, M. Tangney, Bacterial-directed enzyme prodrug therapy, J. Control. Release Off. J. Control. Release Soc. 170 (2013) 120–131. doi: 10.1016/j.jconrel.2013.05.005.
   Google Scholar
• N. Schellmann, P.M. Deckert, D. Bachran, H. Fuchs, C. Bachran, Targeted enzyme prodrug therapies, Mini Rev. Med. Chem. 10 (2010) 887–904. doi: 10.2174/138955710792007196.
   Google Scholar
• Y. Wang, C. Wang, K. Li, X. Song, X. Yan, L. Yu, Z. He, Recent advances of nanomedicine-based strategies in diabetes and complications management: Diagnostics, monitoring, and therapeutics, J. Controlled Release 330 (2021) 618–640. doi: 10.1016/j.jconrel.2021.01.002.
   Google Scholar
• E.-L. Chang, C.-Y. Ting, P.-H. Hsu, Y.-C. Lin, E.-C. Liao, C.-Y. Huang, Y.-C. Chang, H.-L. Chan, C.-S. Chiang, H.-L. Liu, K.-C. Wei, C.-H. Fan, C.-K. Yeh, Angiogenesis-targeting microbubbles combined with ultrasound-mediated gene therapy in brain tumors, J. Controlled Release 255 (2017) 164–175. doi: 10.1016/j.jconrel.2017.04.010.
   Google Scholar
• M. Wu, W. Chen, Y. Chen, H. Zhang, C. Liu, Z. Deng, Z. Sheng, J. Chen, X. Liu, F. Yan, H. Zheng, Focused Ultrasound‐Augmented Delivery of Biodegradable Multifunctional Nanoplatforms for Imaging‐Guided Brain Tumor Treatment, Adv. Sci. 5 (2018) 1700474. doi: 10.1002/advs.201700474.
   Google Scholar
• M.-H. Chan, W. Chen, C.-H. Li, C.-Y. Fang, Y.-C. Chang, D.-H. Wei, R.-S. Liu, M. Hsiao, An Advanced In Situ Magnetic Resonance Imaging and Ultrasonic Theranostics Nanocomposite Platform: Crossing the Blood–Brain Barrier and Improving the Suppression of Glioblastoma Using Iron-Platinum Nanoparticles in Nanobubbles, ACS Appl. Mater. Interfaces 13 (2021) 26759–26769. doi: 10.1021/acsami.1c04990.
   Google Scholar
• R.A. Silverstein, E. González De Valdivia, N. Visa, The Incorporation of 5-Fluorouracil into RNA Affects the Ribonucleolytic Activity of the Exosome Subunit Rrp6, Mol. Cancer Res. 9 (2011) 332–340. doi: 10.1158/1541-7786.MCR-10-0084.
   Google Scholar
• S.M. Stribbling, J. Martin, R.B. Pedley, J.A. Boden, S.K. Sharma, C.J. Springer, Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft, Cancer Chemother. Pharmacol. 40 (1997) 277–284. doi: 10.1007/s002800050659.
   Google Scholar
• F.L. Moolten, J.M. Wells, Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transfered by Retroviral Vectors, JNCI J. Natl. Cancer Inst. 82 (1990) 297–300. doi: 10.1093/jnci/82.4.297.
   Google Scholar
• D. Craperi, J.-M. Vicat, M.-F. Nissou, J. Mathieu, J. Baudier, A.L. Benabid, J.-M. Verna, Increased Bax Expression Is Associated with Cell Death Induced by Ganciclovir in a Herpes Thymidine Kinase Gene-Expressing Glioma Cell Line, Hum. Gene Ther. 10 (1999) 679–688. doi: 10.1089/10430349950018751.
   Google Scholar
• P.A. Robe, F. Princen, D. Martin, B. Malgrange, A. Stevenaert, G. Moonen, J. Gielen, M.-P. Merville, V. Bours, Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system, Biochem. Pharmacol. 60 (2000) 241–249. doi: 10.1016/S0006-2952.(00)00315-4.
   Google Scholar
• H. Chen, G.P. Beardsley, D.M. Coen, Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 17462–17467. doi: 10.1073/pnas.1405981111.
   Google Scholar
• I.V. Alekseenko, E.V. Snezhkov, I.P. Chernov, V.V. Pleshkan, V.K. Potapov, A.V. Sass, G.S. Monastyrskaya, E.P. Kopantzev, T.V. Vinogradova, Y.V. Khramtsov, A.V. Ulasov, A.A. Rosenkranz, A.S. Sobolev, O.A. Bezborodova, A.D. Plyutinskaya, E.R. Nemtsova, R.I. Yakubovskaya, E.D. Sverdlov, Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer, J. Transl. Med. 13 (2015) 78. doi: 10.1186/s12967-015-0433-0.
   Google Scholar
• R.A. Hock, A.D. Miller, Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells, Nature 320 (1986) 275–277. doi: 10.1038/320275a0.
   Google Scholar
• V. Poletti, F. Mavilio, Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases, Viruses 13 (2021) 1526. doi: 10.3390/v13081526.
   Google Scholar
• K.A. High, M.G. Roncarolo, Gene Therapy, N. Engl. J. Med. 381 (2019) 455–464. doi: 10.1056/NEJMra1706910.
   Google Scholar
• R.L. Thangapazham, A. Puri, S. Tele, R. Blumenthal, R.K. Maheshwari, Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells, Int. J. Oncol. 32 (2008) 1119–1123.
   Google Scholar
• A. Gigante, M. Li, S. Junghänel, C. Hirschhäuser, S. Knauer, C. Schmuck, Non-viral transfection vectors: are hybrid materials the way forward?, MedChemComm 10 (2019) 1692–1718. doi: 10.1039/C9MD00275H.
   Google Scholar
• Y. Hattori, Y. Maitani, Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery, Curr. Drug Deliv. 2 (2005) 243–252. doi: 10.2174/1567201054368002.
   Google Scholar
• B.A. Koechlin, F. Rubio, S. Palmer, T. Gabriel, R. Duschinsky, The metabolism of 5-fluorocytosine-214C and of cytosine-14C in the rat and the disposition of 5-fluorocytosine-214C in man, Biochem. Pharmacol. 15 (1966) 435–446. doi: 10.1016/0006-2952.(66)90254-1.
   Google Scholar
• A. Polak, H.J. Scholer, Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance, Chemotherapy 21 (1975) 113–130. doi: 10.1159/000221854.
   Google Scholar
• M. Kilstrup, L.M. Meng, J. Neuhard, P. Nygaard, Genetic evidence for a repressor of synthesis of cytosine deaminase and purine biosynthesis enzymes in Escherichia coli, J. Bacteriol. 171 (1989) 2124–2127. doi: 10.1128/jb.171.4.2124-2127.1989.
   Google Scholar
• C.A. Mullen, M.M. Coale, R. Lowe, R.M. Blaese, Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor, Cancer Res. 54 (1994) 1503–1506.
   Google Scholar
• S. Danielsen, M. Kilstrup, K. Barilla, B. Jochimsen, J. Neuhard, Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase, Mol. Microbiol. 6 (1992) 1335–1344. doi: 10.1111/j.1365-2958.1992.tb00854.x.
   Google Scholar
• E. Titsworth, E. Grunberg, Chemotherapeutic Activity of 5-Fluorocytosine and Amphotericin B Against Candida albicans in Mice, Antimicrob. Agents Chemother. 4 (1973) 306–308. doi: 10.1128/AAC.4.3.306.
   Google Scholar
• Y. Chen, J. Ye, Z. Zhu, W. Zhao, J. Zhou, C. Wu, H. Tang, M. Fan, L. Li, Q. Lin, Y. Xia, Y. Li, J. Li, H. Jia, S. Lu, Z. Zhang, K. Zhao, Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial, J. Clin. Oncol. 37 (2019) 1695–1703. doi: 10.1200/JCO.18.02122.
   Google Scholar
• D.B. Longley, D.P. Harkin, P.G. Johnston, 5-Fluorouracil: mechanisms of action and clinical strategies, Nat. Rev. Cancer 3 (2003) 330–338. doi: 10.1038/nrc1074.
   Google Scholar
• K. Miura, M. Kinouchi, K. Ishida, W. Fujibuchi, T. Naitoh, H. Ogawa, T. Ando, N. Yazaki, K. Watanabe, S. Haneda, C. Shibata, I. Sasaki, 5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs, Cancers 2 (2010) 1717–1730. doi: 10.3390/cancers2031717.
   Google Scholar
• G. Argilés, J. Tabernero, R. Labianca, D. Hochhauser, R. Salazar, T. Iveson, P. Laurent-Puig, P. Quirke, T. Yoshino, J. Taieb, E. Martinelli, D. Arnold, Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 31 (2020) 1291–1305. doi: 10.1016/j.annonc.2020.06.022.
   Google Scholar
• N. Zhang, Y. Yin, S.-J. Xu, W.-S. Chen, 5-Fluorouracil: mechanisms of resistance and reversal strategies, Mol. Basel Switz. 13 (2008) 1551–1569. doi: 10.3390/molecules13081551.
   Google Scholar
• U. Fischer, S. Steffens, S. Frank, N.G. Rainov, K. Schulze-Osthoff, C.M. Kramm, Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells, Oncogene 24 (2005) 1231–1243. doi: 10.1038/sj.onc.1208290.
   Google Scholar
• A.J. Johnson, A. Ardiani, M. Sanchez-Bonilla, M.E. Black, Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications, Cancer Gene Ther. 18 (2011) 533–542. doi: 10.1038/cgt.2011.6.
   Google Scholar
• L.-Y. Deng, J.-P. Wang, Z.-F. Gui, L.-Z. Shen, Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer, World J. Gastroenterol. 17 (2011) 2958–2964. doi: 10.3748/wjg.v17.i24.2958.
   Google Scholar
• S.A. Kaliberov, J.M. Market, G.Y. Gillespie, V. Krendelchtchikova, D. Della Manna, J.C. Sellers, L.N. Kaliberova, M.E. Black, D.J. Buchsbaum, Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma, Gene Ther. 14 (2007) 1111–1119. doi: 10.1038/sj.gt.3302965.
   Google Scholar
• M. Fuchita, A. Ardiani, L. Zhao, K. Serve, B.L. Stoddard, M.E. Black, Bacterial Cytosine Deaminase Mutants Created by Molecular Engineering Show Improved 5-Fluorocytosine–Mediated Cell Killing In vitro and In vivo, Cancer Res. 69 (2009) 4791–4799. doi: 10.1158/0008-5472.CAN-09-0615.
   Google Scholar
• A. Raza, V. Kohila, S.S. Ghosh, Redesigned Escherichia coli cytosine deaminase: a new facet of suicide gene therapy: Cytosine deaminase mutant in suicide gene therapy, J. Gene Med. 17 (2015) 132–139. doi: 10.1002/jgm.2831.
   Google Scholar
• M.S. Hayden, P.S. Linsley, A.R. Wallace, H. Marquardt, D.E. Kerr, Cloning, Overexpression, and Purification of Cytosine Deaminase fromSaccharomyces cerevisiae, Protein Expr. Purif. 12 (1998) 173–184. doi: 10.1006/prep.1997.0839.
   Google Scholar
• S. Leveille, S. Samuel, M.-L. Goulet, J. Hiscott, Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy, Cancer Gene Ther. 18 (2011) 435–443. doi: 10.1038/cgt.2011.14.
   Google Scholar
• C. Richard, W. Duivenvoorden, D. Bourbeau, B. Massie, W. Roa, J. Yau, J. Th’ng, Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy, Cancer Gene Ther. 14 (2007) 57–65. doi: 10.1038/sj.cgt.7700980.
   Google Scholar
• M. Tiraby, C. Cazaux, M. Baron, D. Drocourt, J.-P. Reynes, G. Tiraby, Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine, FEMS Microbiol. Lett. 167 (1998) 41–49. doi: 10.1111/j.1574-6968.1998.tb13205.x.
   Google Scholar
• F. Graepler, Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model, World J. Gastroenterol. 11 (2005) 6910. doi: 10.3748/wjg.v11.i44.6910.
   Google Scholar
• Y. Ding, J. Fan, L. Deng, B. Huang, B. Zhou, Antitumor efficacy of cytosine deaminase-armed vaccinia virus plus 5-fluorocytosine in colorectal cancers, Cancer Cell Int. 20 (2020) 243. doi: 10.1186/s12935-020-01340-6.
   Google Scholar
• W. Liu, J. Zhang, X. Yao, C. Jiang, P. Ni, L. Cheng, J. Liu, S. Ni, Q. Chen, Q. Li, K. Zhou, G. Wang, F. Zhou, Bevacizumab‐enhanced antitumor effect of 5‐fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2‐specificity protein 1 pathway, Cancer Sci. 109 (2018) 3294–3304. doi: 10.1111/cas.13779.
   Google Scholar
• A. Khatri, B. Zhang, E. Doherty, J. Chapman, K. Ow, H. Pwint, R. Martiniello‐Wilks, P.J. Russell, Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice, J. Gene Med. 8 (2006) 1086–1096. doi: 10.1002/jgm.944.
   Google Scholar
• A. Bzowska, E. Kulikowska, D. Shugar, Purine nucleoside phosphorylases: properties, functions, and clinical aspects, Pharmacol. Ther. 88 (2000) 349–425. doi: 10.1016/s0163-7258.(00)00097-8.
   Google Scholar
• M. Friedkin, DESOXYRIBOSE-1-PHOSPHATE, J. Biol. Chem. 184 (1950) 449–459. doi: 10.1016/S0021-9258.(19)50973-5.
   Google Scholar
• F. Canduri, D.M. Dos Santos, R.G. Silva, M.A. Mendes, L.A. Basso, M.S. Palma, W.F. De Azevedo, D.S. Santos, Structures of human purine nucleoside phosphorylase complexed with inosine and ddI, Biochem. Biophys. Res. Commun. 313 (2004) 907–914. doi: 10.1016/j.bbrc.2003.11.179.
   Google Scholar
• P.J. Russell, A. Khatri, Novel gene-directed enzyme prodrug therapies against prostate cancer, Expert Opin. Investig. Drugs 15 (2006) 947–961. doi: 10.1517/13543784.15.8.947.
   Google Scholar
• W.B. Parker, P.W. Allan, S.C. Shaddix, L.M. Rose, H.F. Speegle, G.Y. Gillespie, L.L. Bennett, Metabolism and Metabolic Actions of 6-Methylpurine and 2-Fluoroadenine in Human Cells, Biochem. Pharmacol. 55 (1998) 1673–1681. doi: 10.1016/S0006-2952.(98)00034-3.
   Google Scholar
• E.J. Sorscher, J.S. Hong, P.W. Allan, W.R. Waud, W.B. Parker, In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase, Cancer Chemother. Pharmacol. 70 (2012) 321–329. doi: 10.1007/s00280-012-1908-9.
   Google Scholar
• W.B. Parker, P.W. Allan, W.R. Waud, J.S. Hong, E.J. Sorscher, Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase, Cancer Gene Ther. 18 (2011) 390–398. doi: 10.1038/cgt.2011.4.
   Google Scholar
• S. Afshar, M.R. Sawaya, S.L. Morrison, Structure of a mutant human purine nucleoside phosphorylase with the prodrug, 2‐fluoro‐2′‐deoxyadenosine and the cytotoxic drug, 2‐fluoroadenine, Protein Sci. 18 (2009) 1107–1114. doi: 10.1002/pro.91.
   Google Scholar
• S. Afshar, T. Olafsen, A.M. Wu, S.L. Morrison, Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT, J. Exp. Clin. Cancer Res. 28 (2009) 147. doi: 10.1186/1756-9966-28-147.
   Google Scholar
• P.P. Singh, S. Joshi, P.J. Russell, S. Nair, A. Khatri, Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer, BMC Cancer 11 (2011) 368. doi: 10.1186/1471-2407-11-368.
   Google Scholar
• E.L. Rosenthal, T.K. Chung, W.B. Parker, P.W. Allan, L. Clemons, D. Lowman, J. Hong, F.R. Hunt, J. Richman, R.M. Conry, K. Mannion, W.R. Carroll, L. Nabell, E.J. Sorscher, Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors, Ann. Oncol. 26 (2015) 1481–1487. doi: 10.1093/annonc/mdv196.
   Google Scholar
• A. Romanini, T.C. Chou, J.R. Bertino, Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-cem cell lines sensitive and resistant to methotrexate, Adv. Enzyme Regul. 28 (1989) 323–333. doi: 10.1016/0065-2571.(89)90079-4.
   Google Scholar
• A.D. Al-Qahtani, S.S. Bashraheel, F.B. Rashidi, C.D. O’Connor, A.R. Romero, A. Domling, S.K. Goda, Production of “biobetter” variants of glucarpidase with enhanced enzyme activity, Biomed. Pharmacother. 112 (2019) 108725. doi: 10.1016/j.biopha.2019.108725.
   Google Scholar
• C.J. Springer, P. Antoniw, Bagshawe, F. Searle, G.M.F. Bisset, M. Jarman, Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2, J. Med. Chem. 33 (1990) 677–681. doi: 10.1021/jm00164a034.
   Google Scholar
• B.A. Teicher, E. Frei, Development of alkylating agent-resistant human tumor cell lines, Cancer Chemother. Pharmacol. 21 (1988) 292–298. doi: 10.1007/BF00264194.
   Google Scholar
• E. Frei, B.A. Teicher, S.A. Holden, K.N. Cathcart, Y.Y. Wang, Preclinical studies and clinical correlation of the effect of alkylating dose, Cancer Res. 48 (1988) 6417–6423.
   Google Scholar
• L.C. Davies, F. Friedlos, D. Hedley, J. Martin, L.M. Ogilvie, I.J. Scanlon, C.J. Springer, Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy, J. Med. Chem. 48 (2005) 5321–5328. doi: 10.1021/jm0502182.
   Google Scholar
• R.F. Sherwood, R.G. Melton, S.M. Alwan, P. Hughes, Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method, Eur. J. Biochem. 148 (1985) 447–453. doi: 10.1111/j.1432-1033.1985.tb08860.x.
   Google Scholar
• N.P. Michael, K.A. Chester, R.G. Melton, L. Robson, W. Nicholas, J.A. Boden, R.B. Pedley, R.H.J. Begent, R.F. Sherwood, N.P. Minton, In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein, Immunotechnology 2 (1996) 47–57. doi: 10.1016/1380-2933.(96)00033-4.
   Google Scholar
• F. Friedlos, L. Davies, I. Scanlon, L.M. Ogilvie, J. Martin, S.M. Stribbling, R.A. Spooner, I. Niculescu-Duvaz, R. Marais, C.J. Springer, Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models, Cancer Res. 62 (2002) 1724–1729.
   Google Scholar
• R.A. Spooner, J. Martin, F. Friedlos, R. Marais, C.J. Springer, In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug, Cancer Gene Ther. 7 (2000) 1348–1356. doi: 10.1038/sj.cgt.7700243.
   Google Scholar
• F.B. Rashidi, A.D. AlQhatani, S.S. Bashraheel, S. Shaabani, M.R. Groves, A. Dömling, S.K. Goda, Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment, PloS One 13 (2018) e0196254. doi: 10.1371/journal.pone.0196254.
   Google Scholar
• R.A. Spooner, F. Friedlos, K. Maycroft, S.M. Stribbling, J. Roussel, J. Brueggen, B. Stolz, T. O’Reilly, J. Wood, A. Matter, R. Marais, C.J. Springer, A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs, Br. J. Cancer 88 (2003) 1622–1630. doi: 10.1038/sj.bjc.6600911.
   Google Scholar
• T. Yu, X. Li, Development of ZD2767P–carboxypeptidase G2–ultrasound therapy against cisplatin-resistant cancer, Front. Oncol. 13 (2023) 1151613. doi: 10.3389/fonc.2023.1151613.
   Google Scholar
• E.M. Williams, R.F. Little, A.M. Mowday, M.H. Rich, J.V.E. Chan-Hyams, J.N. Copp, J.B. Smaill, A.V. Patterson, D.F. Ackerley, Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility, Biochem. J. 471 (2015) 131–153. doi: 10.1042/BJ20150650.
   Google Scholar
• N.A. Helsby, S.J. Wheeler, F.B. Pruijn, B.D. Palmer, S. Yang, W.A. Denny, W.R. Wilson, Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation, Chem. Res. Toxicol. 16 (2003) 469–478. doi: 10.1021/tx025662b.
   Google Scholar
• R.J. Knox, F. Friedlos, M. Jarman, J.J. Roberts, A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells, Biochem. Pharmacol. 37 (1988) 4661–4669. doi: 10.1016/0006-2952.(88)90335-8.
   Google Scholar
• W. Cui, B. Gusterson, A.J. Clark, Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway, Gene Ther. 6 (1999) 764–770. doi: 10.1038/sj.gt.3300873.
   Google Scholar
• N.K. Green, I.A. McNeish, R. Doshi, P.F. Searle, D.J. Kerr, L.S. Young, Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector, Int. J. Cancer 104 (2003) 104–112. doi: 10.1002/ijc.10916.
   Google Scholar
• G.U. Dachs, M.A. Hunt, S. Syddall, D.C. Singleton, A.V. Patterson, Bystander or no bystander for gene directed enzyme prodrug therapy, Mol. Basel Switz. 14 (2009) 4517–4545. doi: 10.3390/molecules14114517.
   Google Scholar
• D.H. Palmer, V. Mautner, D. Mirza, S. Oliff, W. Gerritsen, J.R.M. van der Sijp, S. Hubscher, G. Reynolds, S. Bonney, R. Rajaratnam, D. Hull, M. Horne, J. Ellis, A. Mountain, S. Hill, P.A. Harris, P.F. Searle, L.S. Young, N.D. James, D.J. Kerr, Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 22 (2004) 1546–1552. doi: 10.1200/JCO.2004.10.005.
   Google Scholar
• G. Chung-Faye, D. Palmer, D. Anderson, J. Clark, M. Downes, J. Baddeley, S. Hussain, P.I. Murray, P. Searle, L. Seymour, P.A. Harris, D. Ferry, D.J. Kerr, Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 7 (2001) 2662–2668.
   Google Scholar
• P. Patel, J.G. Young, V. Mautner, D. Ashdown, S. Bonney, R.G. Pineda, S.I. Collins, P.F. Searle, D. Hull, E. Peers, J. Chester, D.M. Wallace, A. Doherty, H. Leung, L.S. Young, N.D. James, A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984], Mol. Ther. J. Am. Soc. Gene Ther. 17 (2009) 1292–1299. doi: 10.1038/mt.2009.80.
   Google Scholar
• P.M. Swe, J.N. Copp, L.K. Green, C.P. Guise, A.M. Mowday, J.B. Smaill, A.V. Patterson, D.F. Ackerley, Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954, Biochem. Pharmacol. 84 (2012) 775–783. doi: 10.1016/j.bcp.2012.07.002.
   Google Scholar
• D.C. Singleton, D. Li, S.Y. Bai, S.P. Syddall, J.B. Smaill, Y. Shen, W.A. Denny, W.R. Wilson, A.V. Patterson, The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR), Cancer Gene Ther. 14 (2007) 953–967. doi: 10.1038/sj.cgt.7701088.
   Google Scholar
• D.C. Singleton, A.M. Mowday, C.P. Guise, S.P. Syddall, S.Y. Bai, D. Li, A. Ashoorzadeh, J.B. Smaill, W.R. Wilson, A.V. Patterson, Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit, Cancer Gene Ther. 29 (2022) 1021–1032. doi: 10.1038/s41417-021-00409-2.
   Google Scholar
• N.V. Anufrieva, E.A. Morozova, S.V. Revtovich, N.P. Bazhulina, V.P. Timofeev, Y.V. Tkachev, N.G. Faleev, A.D. Nikulin, T.V. Demidkina, Serine 339 in the Catalysis of γ- and β-Elimination Reactions, Acta Naturae 14 (2022) 50–61. doi: 10.32607/actanaturae.11242.
   Google Scholar
• H. Tanaka, N. Esaki, K. Soda, Properties of L-methionine γ-lyase from Pseudomonas ovalis, Biochemistry 16 (1977) 100–106. doi: 10.1021/bi00620a016.
   Google Scholar
• R.M. Hoffman, Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey, Expert Opin. Biol. Ther. 15 (2015) 21–31. doi: 10.1517/14712598.2015.963050.
   Google Scholar
• V.S. Pokrovsky, L. Abo Qoura, E. Morozova, V.I. Bunik, Predictive markers for efficiency of the amino-acid deprivation therapies in cancer, Front. Med. 9 (2022) 1035356. doi: 10.3389/fmed.2022.1035356.
   Google Scholar
• D.V. Mamaeva, E.A. Morozova, A.D. Nikulin, S.V. Revtovich, S.V. Nikonov, M.B. Garber, T.V. Demidkina, Structure of Citrobacter freundii L -methionine γ-lyase, Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun. 61 (2005) 546–549. doi: 10.1107/S1744309105015447.
   Google Scholar
• S. Revtovich, N. Anufrieva, E. Morozova, V. Kulikova, A. Nikulin, T. Demidkina, Structure of methionine γ-lyase from Clostridium sporogenes, Acta Crystallogr. Sect. F Struct. Biol. Commun. 72 (2016) 65–71. doi: 10.1107/S2053230X15023869.
   Google Scholar
• E.A. Morozova, V.V. Kulikova, D.V. Yashin, N.V. Anufrieva, N.Y. Anisimova, S.V. Revtovich, M.I. Kotlov, Y.F. Belyi, V.S. Pokrovsky, T.V. Demidkina, Kinetic Parameters and Cytotoxic Activity of Recombinant Methionine γ-Lyase from Clostridium tetani, Clostridium sporogenes, Porphyromonas gingivalis and Citrobacter freundii, Acta Naturae 5 (2013) 92–98. doi: 10.32607/20758251-2013-5-3-92-98.
   Google Scholar
• W. Kreis, C. Hession, Biological effects of enzymatic deprivation of L-methionine in cell culture and an experimental tumor, Cancer Res. 33 (1973) 1866–1869.
   Google Scholar
• V.S. Pokrovsky, L. Abo Qoura, E.A. Demidova, Q. Han, R.M. Hoffman, Targeting Methionine Addiction of Cancer Cells with Methioninase, Biochem. Mosc. 88 (2023) 944–952. doi: 10.1134/S0006297923070076.
   Google Scholar
• L. Abo Qoura, K.V. Balakin, R.M. Hoffman, V.S. Pokrovsky, The potential of methioninase for cancer treatment, Biochim. Biophys. Acta BBA - Rev. Cancer 1879 (2024) 189122. doi: 10.1016/j.bbcan.2024.189122.
   Google Scholar
• V.V. Kulikova, N.V. Anufrieva, S.V. Revtovich, A.S. Chernov, G.B. Telegin, E.A. Morozova, T.V. Demidkina, Mutant form C115H of C lostridium sporogenes methionine γ-lyase efficiently cleaves S-Alk(en)yl- l -cysteine sulfoxides to antibacterial thiosulfinates: C115H MGL/Sulfoxide System, IUBMB Life 68 (2016) 830–835. doi: 10.1002/iub.1562.
   Google Scholar
• N.V. Anufrieva, E.A. Morozova, V.V. Kulikova, N.P. Bazhulina, I.V. Manukhov, D.I. Degtev, E.Y. Gnuchikh, A.N. Rodionov, G.B. Zavilgelsky, T.V. Demidkina, Sulfoxides, Analogues of L-Methionine and L-Cysteine As Pro-Drugs against Gram-Positive and Gram-Negative Bacteria, Acta Naturae 7 (2015) 128–135.
   Google Scholar
• V.V. Kulikova, E.A. Morozova, V.S. Koval, P.N. Solyev, T.V. Demidkina, S.V. Revtovich, Thiosulfinates: Cytotoxic and Antitumor Activity, Biochem. Mosc. 88 (2023) 912–923. doi: 10.1134/S0006297923070052.
   Google Scholar
• V. Kulikova, E. Morozova, A. Rodionov, V. Koval, N. Anufrieva, S. Revtovich, T. Demidkina, Non-stereoselective decomposition of (±)-S-alk(en)yl- l -cysteine sulfoxides to antibacterial thiosulfinates catalyzed by C115H mutant methionine γ-lyase from Citrobacter freundii, Biochimie 151 (2018) 42–44. doi: 10.1016/j.biochi.2018.05.011.
   Google Scholar
• V. Koval, E. Morozova, S. Revtovich, A. Lyfenko, A. Chobanian, V. Timofeeva, A. Solovieva, N. Anufrieva, V. Kulikova, T. Demidkina, Characteristics and Stability Assessment of Therapeutic Methionine γ-lyase-Loaded Polyionic Vesicles, ACS Omega 7 (2022) 959–967. doi: 10.1021/acsomega.1c05558.
   Google Scholar
• E. Morozova, L. Abo Qoura, N. Anufrieva, V. Koval, E. Lesnova, A. Kushch, V. Kulikova, S. Revtovich, V.S. Pokrovsky, T. Demidkina, Daidzein-directed methionine γ-lyase in enzyme prodrug therapy against breast cancer, Biochimie 201 (2022) 177–183. doi: 10.1016/j.biochi.2022.05.007.
   Google Scholar
• L. Abo Qoura, E. Morozova, V. Kulikova, S. Karshieva, D. Sokolova, V. Koval, S. Revtovich, T. Demidkina, V.S. Pokrovsky, Methionine γ-Lyase-Daidzein in Combination with S-Propyl-L-cysteine Sulfoxide as a Targeted Prodrug Enzyme System for Malignant Solid Tumor Xenografts, Int. J. Mol. Sci. 23 (2022) 12048. doi: 10.3390/ijms231912048.
   Google Scholar
• A. Stoll, E. Seebeck, Chemical Investigations on Alliin, the Specific Principle of Garlic, in: F.F. Nord (Ed.), Adv. Enzymol. - Relat. Areas Mol. Biol., 1st ed., Wiley, 1951: pp. 377–400. doi: 10.1002/9780470122563.ch8.
   Google Scholar
• A. Roseblade, A. Ung, M. Bebawy, Synthesis and in vitro biological evaluation of thiosulfinate derivatives for the treatment of human multidrug-resistant breast cancer, Acta Pharmacol. Sin. 38 (2017) 1353–1368. doi: 10.1038/aps.2016.170.
   Google Scholar
• T. Miron, M. Wilchek, A. Sharp, Y. Nakagawa, M. Naoi, Y. Nozawa, Y. Akao, Allicin inhibits cell growth and induces apoptosis through the mitochondrial pathway in HL60 and U937 cells, J. Nutr. Biochem. 19 (2008) 524–535. doi: 10.1016/j.jnutbio.2007.06.009.
   Google Scholar
• Y. Zhou, X. Li, W. Luo, J. Zhu, J. Zhao, M. Wang, L. Sang, B. Chang, B. Wang, Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment, Front. Pharmacol. 13 (2022) 903259. doi: 10.3389/fphar.2022.903259.
   Google Scholar
• E. Catanzaro, D. Canistro, V. Pellicioni, F. Vivarelli, C. Fimognari, Anticancer potential of allicin: A review, Pharmacol. Res. 177 (2022) 106118. doi: 10.1016/j.phrs.2022.106118.
   Google Scholar
• Talia Miron, Marina Mironchik, David Mirelman, Meir Wilchek, Aharon Rabinkov, Inhibition of tumor growth by a novel approach: In situ allicin generation using targeted alliinase delivery, Mol. Cancer Ther. 2 (2004) 1295–301.
   Google Scholar
• F.D. Arditti, A. Rabinkov, T. Miron, Y. Reisner, A. Berrebi, M. Wilchek, D. Mirelman, Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate, Mol. Cancer Ther. 4 (2005) 325–332. doi: 10.1158/1535-7163.325.4.2.
   Google Scholar
• H.L. Nicastro, S.A. Ross, J.A. Milner, Garlic and Onions: Their Cancer Prevention Properties, Cancer Prev. Res. (Phila. Pa.) 8 (2015) 181–189. doi: 10.1158/1940-6207.CAPR-14-0172.
   Google Scholar
• B. Zhu, L. Zou, L. Qi, R. Zhong, X. Miao, Allium Vegetables and Garlic Supplements Do Not Reduce Risk of Colorectal Cancer, Based on Meta-analysis of Prospective Studies, Clin. Gastroenterol. Hepatol. 12 (2014) 1991-2001.e4. doi: 10.1016/j.cgh.2014.03.019.
   Google Scholar
• S.A. Adediran, H.B. Dunford, Structure of Horseradish Perosidase Compound I: Kinetic Evidence for the Incorporation of One Oxygen Atom from the Oxidizing Substrate into the Enzyme, Eur. J. Biochem. 132 (1983) 147–150. doi: 10.1111/j.1432-1033.1983.tb07339.x.
   Google Scholar
• A.T. Smith, N. Santama, S. Dacey, M. Edwards, R.C. Bray, R.N. Thorneley, J.F. Burke, Expression of a synthetic gene for horseradish peroxidase C in Escherichia coli and folding and activation of the recombinant enzyme with Ca2+ and heme, J. Biol. Chem. 265 (1990) 13335–13343.
   Google Scholar
• L.P. Candeias, L.K. Folkes, M.F. Dennis, K.B. Patel, S.A. Everett, M.R.L. Stratford, P. Wardman, Free-Radical Intermediates and Stable Products in the Oxidation of Indole-3-acetic acid, J. Phys. Chem. 98 (1994) 10131–10137. doi: 10.1021/j100091a031.
   Google Scholar
• D.-S. Kim, S.-E. Jeon, K.-C. Park, Oxidation of indole-3-acetic acid by horseradish peroxidase induces apoptosis in G361 human melanoma cells, Cell. Signal. 16 (2004) 81–88. doi: 10.1016/s0898-6568.(03)00091-3.
   Google Scholar
• Y.-M. Jeong, M.H. Oh, S.Y. Kim, H. Li, H.-Y. Yun, K.J. Baek, N.S. Kwon, W.Y. Kim, D.-S. Kim, Indole-3-acetic acid/horseradish peroxidase induces apoptosis in TCCSUP human urinary bladder carcinoma cells, Pharm. 65 (2010) 122–126.
   Google Scholar
• C. Huang, L.-Y. Liu, T.-S. Song, L. Ni, L. Yang, X.-Y. Hu, J.-S. Hu, L.-P. Song, Y. Luo, L.-S. Si, Apoptosis of pancreatic cancer BXPC-3 cells induced by indole-3-acetic acid in combination with horseradish peroxidase, World J. Gastroenterol. 11 (2005) 4519–4523. doi: 10.3748/wjg.v11.i29.4519.
   Google Scholar
• J. Tupper, M.R. Stratford, S. Hill, G.M. Tozer, G.U. Dachs, In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer, Cancer Gene Ther. 17 (2010) 420–428. doi: 10.1038/cgt.2009.86.
   Google Scholar
• G. Bonifert, L. Folkes, C. Gmeiner, G. Dachs, O. Spadiut, Recombinant horseradish peroxidase variants for targeted cancer treatment, Cancer Med. 5 (2016) 1194–1203. doi: 10.1002/cam4.668.
   Google Scholar
• M. Dai, J. Liu, D.-E. Chen, Y. Rao, Z.-J. Tang, W.-Z. Ho, C.-Y. Dong, Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice, Cancer Gene Ther. 19 (2012) 77–83. doi: 10.1038/cgt.2011.65.
   Google Scholar
• D. Humer, V. Furlanetto, A.-K. Schruef, A. Wlodarczyk, M. Kuttke, C. Divne, O. Spadiut, Potential of unglycosylated horseradish peroxidase variants for enzyme prodrug cancer therapy, Biomed. Pharmacother. 142 (2021) 112037. doi: 10.1016/j.biopha.2021.112037.
   Google Scholar
• U. Wittstock, K. Meier, F. Dörr, B.M. Ravindran, NSP-Dependent Simple Nitrile Formation Dominates upon Breakdown of Major Aliphatic Glucosinolates in Roots, Seeds, and Seedlings of Arabidopsis thaliana Columbia-0, Front. Plant Sci. 7 (2016). doi: 10.3389/fpls.2016.01821.
   Google Scholar
• T. Oliviero, R. Verkerk, M. Dekker, Isothiocyanates from Brassica Vegetables-Effects of Processing, Cooking, Mastication, and Digestion, Mol. Nutr. Food Res. 62 (2018) 1701069. doi: 10.1002/mnfr.201701069.
   Google Scholar
• A. Pessina, R.M. Thomas, S. Palmieri, P.L. Luisi, An improved method for the purification of myrosinase and its physicochemical characterization, Arch. Biochem. Biophys. 280 (1990) 383–389. doi: 10.1016/0003-9861.(90)90346-Z.
   Google Scholar
• O. Leoni, R. Iori, S. Palmieri, E. Esposito, E. Menegatti, R. Cortesi, C. Nastruzzi, Myrosinase-generated isothiocyanate from glucosinolates: Isolation, characterization and in vitro antiproliferative studies, Bioorg. Med. Chem. 5 (1997) 1799–1806. doi: 10.1016/S0968-0896.(97)00112-0.
   Google Scholar
• J. Chiang, F. Tsai, Y. Hsu, M. Yin, H. Chiu, J. Yang, Sensitivity of allyl isothiocyanate to induce apoptosis via ER stress and the mitochondrial pathway upon ROS production in colorectal adenocarcinoma cells, Oncol. Rep. (2020). doi: 10.3892/or.2020.7700.
   Google Scholar
• K.-C. Lai, C.-C. Lu, Y.-J. Tang, J.-H. Chiang, D.-H. Kuo, F.-A. Chen, I.-L. Chen, J.-S. Yang, Allyl isothiocyanate inhibits cell metastasis through suppression of the MAPK pathways in epidermal growth factor-stimulated HT29 human colorectal adenocarcinoma cells, Oncol. Rep. 31 (2014) 189–196. doi: 10.3892/or.2013.2865.
   Google Scholar
• G. Qin, P. Li, Z. Xue, Effect of allyl isothiocyanate on the viability and apoptosis of the human cervical cancer HeLa cell line in�vitro, Oncol. Lett. (2018). doi: 10.3892/ol.2018.8428.
   Google Scholar
• R.-K. Lin, N. Zhou, Y.L. Lyu, Y.-C. Tsai, C.-H. Lu, J. Kerrigan, Y. Chen, Z. Guan, T.-S. Hsieh, L.F. Liu, Dietary Isothiocyanate-induced Apoptosis via Thiol Modification of DNA Topoisomerase IIα, J. Biol. Chem. 286 (2011) 33591–33600. doi: 10.1074/jbc.M111.258137.
   Google Scholar
• K. Tripathi, U.K. Hussein, R. Anupalli, R. Barnett, L. Bachaboina, J. Scalici, R.P. Rocconi, L.B. Owen, G.A. Piazza, K. Palle, Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation, Oncotarget 6 (2015) 5237–5252. doi: 10.18632/oncotarget.3026.
   Google Scholar
• I.E. Popova, M.J. Morra, Simultaneous Quantification of Sinigrin, Sinalbin, and Anionic Glucosinolate Hydrolysis Products in Brassica juncea and Sinapis alba Seed Extracts Using Ion Chromatography, J. Agric. Food Chem. 62 (2014) 10687–10693. doi: 10.1021/jf503755m.
   Google Scholar
• Y. Zhang, Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action, Mutat. Res. Mol. Mech. Mutagen. 555 (2004) 173–190. doi: 10.1016/j.mrfmmm.2004.04.017.
   Google Scholar
• A. Tarar, C.-A. Peng, Antineoplastic Potency of Sinigrin-functionalized Silver Nanoparticles on Tumor Cells Transfected with Myrosinase-encoded Plasmids, BioNanoScience (2023). doi: 10.1007/s12668-023-01233-8.
   Google Scholar
• R.J. Francis, S.K. Sharma, C. Springer, A.J. Green, L.D. Hope-Stone, L. Sena, J. Martin, K.L. Adamson, A. Robbins, L. Gumbrell, D. O’Malley, E. Tsiompanou, H. Shahbakhti, S. Webley, D. Hochhauser, A.J. Hilson, D. Blakey, R.H.J. Begent, A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours, Br. J. Cancer 87 (2002) 600–607. doi: 10.1038/sj.bjc.6600517.
   Google Scholar
• G. Chung-Faye, D. Palmer, D. Anderson, J. Clark, M. Downes, J. Baddeley, S. Hussain, P.I. Murray, P. Searle, L. Seymour, P.A. Harris, D. Ferry, D.J. Kerr, Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 7 (2001) 2662–2668.
   Google Scholar
• M.S. Chen, W.P. Summers, J. Walker, W.C. Summers, W.H. Prusoff, Characterization of pyrimidine deoxyribonucleoside kinase (thymidine kinase) and thymidylate kinase as a multifunctional enzyme in cells transformed by herpes simplex virus type 1 and in cells infected with mutant strains of herpes simplex virus, J. Virol. 30 (1979) 942–945. doi: 10.1128/jvi.30.3.942-945.1979.
   Google Scholar
• J.N. Champness, M.S. Bennett, F. Wien, R. Visse, W.C. Summers, P. Herdewijn, E. De Clercq, T. Ostrowski, R.L. Jarvest, M.R. Sanderson, Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands, Proteins Struct. Funct. Genet. 32 (1998) 350–361. doi: ;2-8.
   Google Scholar
• P.T. Golumbek, F.M. Hamzeh, E.M. Jaffee, H. Levitsky, P.S. Lietman, D.M. Pardoll, Herpes Simplex-1 Virus Thymidine Kinase Gene Is Unable to Completely Eliminate Live, Nonimmunogenic Tumor Cell Vaccines:, J. Immunother. 12 (1992) 224–230. doi: 10.1097/00002371-199211000-00002.
   Google Scholar
• A. Abe, T. Takeo, N. Emi, M. Tanimoto, R. Ueda, J.-K. Yee, T. Friedmann, H. Saito, Transduction of a Drug-Sensitive Toxic Gene into Human Leukemia Cell Lines with a Novel Retroviral Vector, Exp. Biol. Med. 203 (1993) 354–359. doi: 10.3181/00379727-203-43611.
   Google Scholar
• K. Kato, J. Yoshida, M. Mizuno, K. Sugita, N. Emi, Retroviral Transfer of Herpes Simplex Thymidine Kinase Gene into Glioma Cells Causes Targeting of Gancyclovir Cytotoxic Effect, Neurol. Med. Chir. (Tokyo) 34 (1994) 339–344. doi: 10.2176/nmc.34.339.
   Google Scholar
• D. Barba, J. Hardin, J. Ray, F.H. Gage, Thymidine kinase-mediated killing of rat brain tumors, J. Neurosurg. 79 (1993) 729–735. doi: 10.3171/jns.1993.79.5.0729.
   Google Scholar
• W.R. Smythe, H.C. Hwang, K.M. Amin, S.L. Eck, B.L. Davidson, J.M. Wilson, L.R. Kaiser, S.M. Albelda, Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system, Cancer Res. 54 (1994) 2055–2059.
   Google Scholar
• T. Osaki, Y. Tanio, I. Tachibana, S. Hosoe, T. Kumagai, I. Kawase, S. Oikawa, T. Kishimoto, Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene, Cancer Res. 54 (1994) 5258–5261.
   Google Scholar
• S. Kuriyama, T. Sakamoto, K. Masui, T. Nakatani, K. Tominaga, M. Kikukawa, M. Yoshikawa, K. Ikenaka, H. Fukui, T. Tsujii, Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma, Int. J. Cancer 71 (1997) 470–475. doi: ;2-I.
   Google Scholar
• G. Plautz, E.G. Nabel, G.J. Nabel, Selective elimination of recombinant genes in vivo with a suicide retroviral vector, New Biol. 3 (1991) 709–715.
   Google Scholar
• L.K. Aguilar, L.A. Shirley, V.M. Chung, C.L. Marsh, J. Walker, W. Coyle, H. Marx, T. Bekaii-Saab, G.B. Lesinski, B. Swanson, D. Sanchez, A.G. Manzanera, E. Aguilar-Cordova, M. Bloomston, Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma, Cancer Immunol. Immunother. 64 (2015) 727–736. doi: 10.1007/s00262-015-1679-3.
   Google Scholar
• B. Sangro, G. Mazzolini, M. Ruiz, J. Ruiz, J. Quiroga, I. Herrero, C. Qian, A. Benito, J. Larrache, C. Olagüe, J. Boan, I. Peñuelas, B. Sádaba, J. Prieto, A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma, Cancer Gene Ther. 17 (2010) 837–843. doi: 10.1038/cgt.2010.40.
   Google Scholar
• L. Wu, W.-B. Zhou, F. Shen, W. Liu, H.-W. Wu, S.-J. Zhou, S.-W. Li, Connexin32‑mediated antitumor effects of suicide gene therapy against hepatocellular carcinoma: In vitro and in vivo anticancer activity, Mol. Med. Rep. 13 (2016) 3213–3219. doi: 10.3892/mmr.2016.4895.
   Google Scholar
• M. Adachi, J. Sampath, L. Lan, D. Sun, P. Hargrove, R. Flatley, A. Tatum, M.Z. Edwards, M. Wezeman, L. Matherly, R. Drake, J. Schuetz, Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing, J. Biol. Chem. 277 (2002) 38998–39004. doi: 10.1074/jbc.M203262200.
   Google Scholar
• W. Hu, W. Liu, Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population, In Vitro Cell. Dev. Biol. Anim. 46 (2010) 497–501. doi: 10.1007/s11626-010-9274-6.
   Google Scholar
• E. Preuss, A. Muik, K. Weber, J. Otte, D. von Laer, B. Fehse, Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect, J. Mol. Med. Berl. Ger. 89 (2011) 1113–1124. doi: 10.1007/s00109-011-0777-8.
   Google Scholar
• S.-Y. Park, W. Lee, J. Lee, I.-S. Kim, Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase, Cancer Lett. 261 (2008) 205–214. doi: 10.1016/j.canlet.2007.11.011.
   Google Scholar
• T. Xiong, Y. Li, F. Ni, F. Zhang, Monitoring of bystander effect of herpes simplex virus thymidine kinase/acyclovir system using fluorescence resonance energy transfer technique, J. Biomed. Nanotechnol. 8 (2012) 74–79. doi: 10.1166/jbn.2012.1357.
   Google Scholar
• X. Li, P. Zhou, L. Wang, S. Tian, Y. Qian, L. Chen, P. Zhang, The targeted gene (KDRP-CD/TK) therapy of breast cancer mediated by SonoVue and ultrasound irradiation in vitro, Ultrasonics 52 (2012) 186–191. doi: 10.1016/j.ultras.2011.08.002.
   Google Scholar
• B. Zhang, M. Chen, Y. Zhang, W. Chen, L. Zhang, L. Chen, An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma, PLOS ONE 13 (2018) e0196686. doi: 10.1371/journal.pone.0196686.
   Google Scholar
• A. Aoi, Y. Watanabe, S. Mori, M. Takahashi, G. Vassaux, T. Kodama, Herpes Simplex Virus Thymidine Kinase-Mediated Suicide Gene Therapy Using Nano/Microbubbles and Ultrasound, Ultrasound Med. Biol. 34 (2008) 425–434. doi: 10.1016/j.ultrasmedbio.2007.09.004.
   Google Scholar
• J. Li, P. Zhou, L. Li, Y. Zhang, Y. Shao, L. Tang, S. Tian, Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and αVβ3 Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells, PLOS ONE 11 (2016) e0158592. doi: 10.1371/journal.pone.0158592.
   Google Scholar
• C. Hu, D. Jiang, M. Wu, J. Wang, R. Zhang, Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of VEGFR2-targeted CD-TK-loaded cationic nanobubbles in the treatment of bladder cancer, J. Cancer Res. Clin. Oncol. 146 (2020) 1415–1426. doi: 10.1007/s00432-020-03160-7.
   Google Scholar
• Y. Liu, Y. Zhang, D. Du, X. Gu, X. Zhang, G. Hong, X. Lai, Nanotargeted Cationic Lipid Microbubbles Carrying HSV‐TK Gene Inhibit the Development of Subcutaneous Liver Tumor Model After HIFU Ablation, J. Ultrasound Med. 43 (2024) 95–107. doi: 10.1002/jum.16342.
   Google Scholar
• R. Devulapally, T. Lee, A. Barghava-Shah, T.V. Sekar, K. Foygel, S.V. Bachawal, J.K. Willmann, R. Paulmurugan, Ultrasound-guided delivery of thymidine kinase–nitroreductase dual therapeutic genes by PEGylated-PLGA/PEI nanoparticles for enhanced triple negative breast cancer therapy, Nanomed. 13 (2018) 1051–1066. doi: 10.2217/nnm-2017-0328.
   Google Scholar
• Y.I. Yoon, Y.-S. Kwon, H.-S. Cho, S.-H. Heo, K.S. Park, S.G. Park, S.-H. Lee, S.I. Hwang, Y.I. Kim, H.J. Jae, G.-J. Ahn, Y.-S. Cho, H. Lee, H.J. Lee, T.-J. Yoon, Ultrasound-Mediated Gene and Drug Delivery Using a Microbubble-Liposome Particle System, Theranostics 4 (2014) 1133–1144. doi: 10.7150/thno.9945.
   Google Scholar
• S. Hernot, A.L. Klibanov, Microbubbles in ultrasound-triggered drug and gene delivery, Adv. Drug Deliv. Rev. 60 (2008) 1153–1166. doi: 10.1016/j.addr.2008.03.005.
   Google Scholar
• A. Goto, Y. Anraku, S. Fukushima, A. Kishimura, Increased Enzyme Loading in PICsomes via Controlling Membrane Permeability Improves Enzyme Prodrug Cancer Therapy Outcome, Polymers 15 (2023) 1368. doi: 10.3390/polym15061368.
   Google Scholar
• E.A. Morozova, V.V. Kulikova, N.V. Anufrieva, A.N. Minakov, A.S. Chernov, G.B. Telegin, S.V. Revtovich, V.S. Koval, T.V. Demidkina, Methionine γ-lyase in enzyme prodrug therapy: An improvement of pharmacokinetic parameters of the enzyme, Int. J. Biol. Macromol. 140 (2019) 1277–1283. doi: 10.1016/j.ijbiomac.2019.08.224.
   Google Scholar
• E. Donath, G.B. Sukhorukov, F. Caruso, S.A. Davis, H. Möhwald, Novel Hollow Polymer Shells by Colloid-Templated Assembly of Polyelectrolytes, Angew. Chem. Int. Ed. 37 (1998) 2201–2205. doi: ;2-E.
   Google Scholar
• A. Koide, A. Kishimura, K. Osada, W.-D. Jang, Y. Yamasaki, K. Kataoka, Semipermeable Polymer Vesicle (PICsome) Self-Assembled in Aqueous Medium from a Pair of Oppositely Charged Block Copolymers: Physiologically Stable Micro-/Nanocontainers of Water-Soluble Macromolecules, J. Am. Chem. Soc. 128 (2006) 5988–5989. doi: 10.1021/ja057993r.
   Google Scholar
• Y. Anraku, A. Kishimura, M. Kamiya, S. Tanaka, T. Nomoto, K. Toh, Y. Matsumoto, S. Fukushima, D. Sueyoshi, M.R. Kano, Y. Urano, N. Nishiyama, K. Kataoka, Systemically Injectable Enzyme‐Loaded Polyion Complex Vesicles as In Vivo Nanoreactors Functioning in Tumors, Angew. Chem. Int. Ed. 55 (2016) 560–565. doi: 10.1002/anie.201508339.
   Google Scholar
• A.A.-W.M.M. Japir, W. Ke, J. Li, J.F. Mukerabigwi, A. Ibrahim, Y. Wang, X. Li, Q. Zhou, F. Mohammed, Z. Ge, Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy, J. Controlled Release 339 (2021) 418–429. doi: 10.1016/j.jconrel.2021.10.015.
   Google Scholar
• T. Nishimura, Y. Sasaki, K. Akiyoshi, Biotransporting Self‐Assembled Nanofactories Using Polymer Vesicles with Molecular Permeability for Enzyme Prodrug Cancer Therapy, Adv. Mater. 29 (2017) 1702406. doi: 10.1002/adma.201702406.
   Google Scholar
• M. Hori, H. Cabral, K. Toh, A. Kishimura, K. Kataoka, Robust Polyion Complex Vesicles (PICsomes) under Physiological Conditions Reinforced by Multiple Hydrogen Bond Formation Derived by Guanidinium Groups, Biomacromolecules 19 (2018) 4113–4121. doi: 10.1021/acs.biomac.8b01097.
   Google Scholar
• M.W. Freeman, A. Arrott, J.H.L. Watson, Magnetism in Medicine, J. Appl. Phys. 31 (1960) S404–S405. doi: 10.1063/1.1984765.
   Google Scholar
• A.S. Lübbe, C. Bergemann, H. Riess, F. Schriever, P. Reichardt, K. Possinger, M. Matthias, B. Dörken, F. Herrmann, R. Gürtler, P. Hohenberger, N. Haas, R. Sohr, B. Sander, A.J. Lemke, D. Ohlendorf, W. Huhnt, D. Huhn, Clinical experiences with magnetic drug targeting: a phase I study with 4’-epidoxorubicin in 14 patients with advanced solid tumors, Cancer Res. 56 (1996) 4686–4693.
   Google Scholar
• H. Cabral, J. Li, K. Miyata, K. Kataoka, Controlling the biodistribution and clearance of nanomedicines, Nat. Rev. Bioeng. 2 (2023) 214–232. doi: 10.1038/s44222-023-00138-1.
   Google Scholar
• B. Polyak, G. Friedman, Magnetic targeting for site-specific drug delivery: applications and clinical potential, Expert Opin. Drug Deliv. 6 (2009) 53–70. doi: 10.1517/17425240802662795.
   Google Scholar
• B. Torres-Herrero, I. Armenia, M. Alleva, L. Asín, S. Correa, C. Ortiz, Y. Fernández-Afonso, L. Gutiérrez, J.M. De La Fuente, L. Betancor, V. Grazú, Remote Activation of Enzyme Nanohybrids for Cancer Prodrug Therapy Controlled by Magnetic Heating, ACS Nano 17 (2023) 12358–12373. doi: 10.1021/acsnano.3c01599.
   Google Scholar
• S. Correa, S. Puertas, L. Gutiérrez, L. Asín, J. Martínez De La Fuente, V. Grazú, L. Betancor, Design of stable magnetic hybrid nanoparticles of Si-entrapped HRP, PLOS ONE 14 (2019) e0214004. doi: 10.1371/journal.pone.0214004.
   Google Scholar
• P. Ball, R. Hobbs, S. Anderson, E. Thompson, V. Gwenin, C. Von Ruhland, C. Gwenin, The YfkO Nitroreductase from Bacillus Licheniformis on Gold-Coated Superparamagnetic Nanoparticles: Towards a Novel Directed Enzyme Prodrug Therapy Approach, Pharmaceutics 13 (2021) 517. doi: 10.3390/pharmaceutics13040517.
   Google Scholar
• S. Roy, S.D. Curry, C. Corbella Bagot, E.N. Mueller, A.M. Mansouri, W. Park, J.N. Cha, A.P. Goodwin, Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles, ACS Nano 16 (2022) 15873–15883. doi: 10.1021/acsnano.2c02558.
   Google Scholar
• B.S. Zolnik, Á. González-Fernández, N. Sadrieh, M.A. Dobrovolskaia, Minireview: Nanoparticles and the Immune System, Endocrinology 151 (2010) 458–465. doi: 10.1210/en.2009-1082.
   Google Scholar
• G. Huysmans, A. Ranquin, L. Wyns, J. Steyaert, P. Van Gelder, Encapsulation of therapeutic nucleoside hydrolase in functionalised nanocapsules, J. Controlled Release 102 (2005) 171–179. doi: 10.1016/j.jconrel.2004.10.002.
   Google Scholar
• R. Kumar, A.N. Maitra, P.K. Patanjali, P. Sharma, Hollow gold nanoparticles encapsulating horseradish peroxidase, Biomaterials 26 (2005) 6743–6753. doi: 10.1016/j.biomaterials.2005.04.045.
   Google Scholar
• T.D. Dziubla, A. Karim, V.R. Muzykantov, Polymer nanocarriers protecting active enzyme cargo against proteolysis, J. Controlled Release 102 (2005) 427–439. doi: 10.1016/j.jconrel.2004.10.017.
   Google Scholar
• P. Wu, J. Han, Y. Gong, C. Liu, H. Yu, N. Xie, Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications, Pharmaceutics 14 (2022) 1990. doi: 10.3390/pharmaceutics14101990.
   Google Scholar
• X. Cao, C. Chen, H. Yu, P. Wang, Horseradish peroxidase-encapsulated chitosan nanoparticles for enzyme-prodrug cancer therapy, Biotechnol. Lett. 37 (2015) 81–88. doi: 10.1007/s10529-014-1664-5.
   Google Scholar
• N. Gupta, R.K. Sharma, A. Maitra, A. Shrivastava, In-vitro and in-vivo efficacy of hollow gold nanoparticles encapsulating horseradish peroxidase: Oxidative stress-mediated tumor cell killing, J. Drug Deliv. Sci. Technol. 79 (2023) 103979. doi: 10.1016/j.jddst.2022.103979.
   Google Scholar
• M. Konhäuser, V.K. Kannaujiya, J. Kaltbeitzel, P. Winterwerber, E. Böhm, B. Breitenbach, P.R. Wich, Dual-Responsive Enzyme–Polysaccharide Conjugate as a Nanocarrier System for Enzyme Prodrug Therapy, Biomacromolecules 24 (2023) 2138–2148. doi: 10.1021/acs.biomac.3c00031.
   Google Scholar
• L. Cheng, F. Zhang, S. Wang, X. Pan, S. Han, S. Liu, J. Ma, H. Wang, H. Shen, H. Liu, Q. Yuan, Activation of Prodrugs by NIR‐Triggered Release of Exogenous Enzymes for Locoregional Chemo‐photothermal Therapy, Angew. Chem. Int. Ed. 58 (2019) 7728–7732. doi: 10.1002/anie.201902476.
   Google Scholar
• J. Paggetti, F. Haderk, M. Seiffert, B. Janji, U. Distler, W. Ammerlaan, Y.J. Kim, J. Adam, P. Lichter, E. Solary, G. Berchem, E. Moussay, Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts, Blood 126 (2015) 1106–1117. doi: 10.1182/blood-2014-12-618025.
   Google Scholar
• N. Heldring, I. Mäger, M.J.A. Wood, K. Le Blanc, S.E.L. Andaloussi, Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles, Hum. Gene Ther. 26 (2015) 506–517. doi: 10.1089/hum.2015.072.
   Google Scholar
• M. Tibensky, J. Jakubechova, U. Altanerova, A. Pastorakova, B. Rychly, L. Baciak, B. Mravec, C. Altaner, Gene-Directed Enzyme/Prodrug Therapy of Rat Brain Tumor Mediated by Human Mesenchymal Stem Cell Suicide Gene Extracellular Vesicles In Vitro and In Vivo, Cancers 14 (2022) 735. doi: 10.3390/cancers14030735.
   Google Scholar
• M. Kanada, B.D. Kim, J.W. Hardy, J.A. Ronald, M.H. Bachmann, M.P. Bernard, G.I. Perez, A.A. Zarea, T.J. Ge, A. Withrow, S.A. Ibrahim, V. Toomajian, S.S. Gambhir, R. Paulmurugan, C.H. Contag, Microvesicle-Mediated Delivery of Minicircle DNA Results in Effective Gene-Directed Enzyme Prodrug Cancer Therapy, Mol. Cancer Ther. 18 (2019) 2331–2342. doi: 10.1158/1535-7163.MCT-19-0299.
   Google Scholar
• C. Song, J. Xiang, J. Tang, D.G. Hirst, J. Zhou, K.-M. Chan, G. Li, Thymidine Kinase Gene Modified Bone Marrow Mesenchymal Stem Cells as Vehicles for Antitumor Therapy, Hum. Gene Ther. 22 (2011) 439–449. doi: 10.1089/hum.2010.116.
   Google Scholar
• M. Matuskova, K. Hlubinova, A. Pastorakova, L. Hunakova, V. Altanerova, C. Altaner, L. Kucerova, HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells, Cancer Lett. 290 (2010) 58–67. doi: 10.1016/j.canlet.2009.08.028.
   Google Scholar
• C. Altaner, V. Altanerova, M. Cihova, K. Ondicova, B. Rychly, L. Baciak, B. Mravec, Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario, Int. J. Cancer 134 (2014) 1458–1465. doi: 10.1002/ijc.28455.
   Google Scholar
• V. Altanerova, M. Cihova, M. Babic, B. Rychly, K. Ondicova, B. Mravec, C. Altaner, Human adipose tissue‐derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma, Int. J. Cancer 130 (2012) 2455–2463. doi: 10.1002/ijc.26278.
   Google Scholar
• A. Mizrak, M.F. Bolukbasi, G.B. Ozdener, G.J. Brenner, S. Madlener, E.P. Erkan, T. Ströbel, X.O. Breakefield, O. Saydam, Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth, Mol. Ther. 21 (2013) 101–108. doi: 10.1038/mt.2012.161.
   Google Scholar
• M. Harada-Shiba, K. Yamauchi, A. Harada, I. Takamisawa, K. Shimokado, K. Kataoka, Polyion complex micelles as vectors in gene therapy – pharmacokinetics and in vivo gene transfer, Gene Ther. 9 (2002) 407–414. doi: 10.1038/sj.gt.3301665.
   Google Scholar
• M.A.M. Subbaiah, J. Rautio, N.A. Meanwell, Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates, Chem. Soc. Rev. 53 (2024) 2099–2210. doi: 10.1039/D2CS00957A.
   Google Scholar
• J. Liu, Y. Huang, A. Kumar, A. Tan, S. Jin, A. Mozhi, X.-J. Liang, pH-Sensitive nano-systems for drug delivery in cancer therapy, Biotechnol. Adv. 32 (2014) 693–710. doi: 10.1016/j.biotechadv.2013.11.009.
   Google Scholar
• M. Stubbs, P.M.J. McSheehy, J.R. Griffiths, C.L. Bashford, Causes and consequences of tumour acidity and implications for treatment, Mol. Med. Today 6 (2000) 15–19. doi: 10.1016/S1357-4310.(99)01615-9.
   Google Scholar
• D. Trachootham, J. Alexandre, P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nat. Rev. Drug Discov. 8 (2009) 579–591. doi: 10.1038/nrd2803.
   Google Scholar
• L. Kennedy, J.K. Sandhu, M.-E. Harper, M. Cuperlovic-Culf, Role of Glutathione in Cancer: From Mechanisms to Therapies, Biomolecules 10 (2020) 1429. doi: 10.3390/biom10101429.
   Google Scholar
• J. Fang, H. Nakamura, H. Maeda, The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv. Drug Deliv. Rev. 63 (2011) 136–151. doi: 10.1016/j.addr.2010.04.009.
   Google Scholar
• M.-H. Lin, C.-F. Hung, C.-Y. Hsu, Z.-C. Lin, J.-Y. Fang, Prodrugs in Combination with Nanocarriers as a Strategy for Promoting Antitumoral Efficiency, Future Med. Chem. 11 (2019) 2131–2150. doi: 10.4155/fmc-2018-0388.
   Google Scholar
• I. Giang, E.L. Boland, G.M.K. Poon, Prodrug Applications for Targeted Cancer Therapy, AAPS J. 16 (2014) 899–913. doi: 10.1208/s12248-014-9638-z.
   Google Scholar
• A. Warnecke, I. Fichtner, D. Garmann, U. Jaehde, F. Kratz, Synthesis and Biological Activity of Water-Soluble Maleimide Derivatives of the Anticancer Drug Carboplatin Designed as Albumin-Binding Prodrugs, Bioconjug. Chem. 15 (2004) 1349–1359. doi: 10.1021/bc049829j.
   Google Scholar
• F. Kratz, A. Warnecke, K. Scheuermann, C. Stockmar, J. Schwab, P. Lazar, P. Drückes, N. Esser, J. Drevs, D. Rognan, C. Bissantz, C. Hinderling, G. Folkers, I. Fichtner, C. Unger, Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound, J. Med. Chem. 45 (2002) 5523–5533. doi: 10.1021/jm020276c.
   Google Scholar
• T. Legigan, J. Clarhaut, B. Renoux, I. Tranoy-Opalinski, A. Monvoisin, J.-M. Berjeaud, F. Guilhot, S. Papot, Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin, J. Med. Chem. 55 (2012) 4516–4520. doi: 10.1021/jm300348r.
   Google Scholar
• B. Tirkey, B. Bhushan, S. Uday Kumar, P. Gopinath, Prodrug encapsulated albumin nanoparticles as an alternative approach to manifest anti-proliferative effects of suicide gene therapy, Mater. Sci. Eng. C 73 (2017) 507–515. doi: 10.1016/j.msec.2016.12.108.
   Google Scholar
• A. Rosolen, E. Frascella, C.D. Francesco, A. Todesco, M. Petrone, M. Mehtali, F. Zacchello, L. Zanesco, M. Scarpa, In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma, Gene Ther. 5 (1998) 113–120. doi: 10.1038/sj.gt.3300559.
   Google Scholar
• A. Ardiani, M. Sanchez-Bonilla, M.E. Black, Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo, Cancer Gene Ther. 17 (2010) 86–96. doi: 10.1038/cgt.2009.60.
   Google Scholar
• S. Shetty, P.F. Lalor, D.H. Adams, Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity, Nat. Rev. Gastroenterol. Hepatol. 15 (2018) 555–567. doi: 10.1038/s41575-018-0020-y.
   Google Scholar
• S.K. Soininen, K.-S. Vellonen, A.T. Heikkinen, S. Auriola, V.-P. Ranta, A. Urtti, M. Ruponen, Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling, Mol. Pharm. 13 (2016) 1358–1365. doi: 10.1021/acs.molpharmaceut.6b00008.
   Google Scholar
• B. Yameen, W.I. Choi, C. Vilos, A. Swami, J. Shi, O.C. Farokhzad, Insight into nanoparticle cellular uptake and intracellular targeting, J. Controlled Release 190 (2014) 485–499. doi: 10.1016/j.jconrel.2014.06.038.
   Google Scholar
• A.P. Singh, D.K. Shah, Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE, Drug Metab. Dispos. 45 (2017) 1120–1132. doi: 10.1124/dmd.117.076414.
   Google Scholar
• N. Hoshyar, S. Gray, H. Han, G. Bao, The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction, Nanomed. 11 (2016) 673–692. doi: 10.2217/nnm.16.5.
   Google Scholar
• K. Niikura, T. Matsunaga, T. Suzuki, S. Kobayashi, H. Yamaguchi, Y. Orba, A. Kawaguchi, H. Hasegawa, K. Kajino, T. Ninomiya, K. Ijiro, H. Sawa, Gold Nanoparticles as a Vaccine Platform: Influence of Size and Shape on Immunological Responses in Vitro and in Vivo, ACS Nano 7 (2013) 3926–3938. doi: 10.1021/nn3057005.
   Google Scholar
• J.A. Champion, S. Mitragotri, Shape Induced Inhibition of Phagocytosis of Polymer Particles, Pharm. Res. 26 (2009) 244–249. doi: 10.1007/s11095-008-9626-z.
   Google Scholar
• B.D. Chithrani, A.A. Ghazani, W.C.W. Chan, Determining the Size and Shape Dependence of Gold Nanoparticle Uptake into Mammalian Cells, Nano Lett. 6 (2006) 662–668. doi: 10.1021/nl052396o.
   Google Scholar
• B.D. Chithrani, W.C.W. Chan, Elucidating the Mechanism of Cellular Uptake and Removal of Protein-Coated Gold Nanoparticles of Different Sizes and Shapes, Nano Lett. 7 (2007) 1542–1550. doi: 10.1021/nl070363y.
   Google Scholar
• D.R. Elias, A. Poloukhtine, V. Popik, A. Tsourkas, Effect of ligand density, receptor density, and nanoparticle size on cell targeting, Nanomedicine Nanotechnol. Biol. Med. 9 (2013) 194–201. doi: 10.1016/j.nano.2012.05.015.
   Google Scholar
• S. Zhang, A. Nelson, P.A. Beales, Freezing or Wrapping: The Role of Particle Size in the Mechanism of Nanoparticle–Biomembrane Interaction, Langmuir 28 (2012) 12831–12837. doi: 10.1021/la301771b.
   Google Scholar
• W.B. Cai, H.L. Yang, J. Zhang, J.K. Yin, Y.L. Yang, L.J. Yuan, L. Zhang, Y.Y. Duan, The Optimized Fabrication of Nanobubbles as Ultrasound Contrast Agents for Tumor Imaging, Sci. Rep. 5 (2015) 13725. doi: 10.1038/srep13725.
   Google Scholar
• S. Karpitschka, E. Dietrich, J.R.T. Seddon, H.J.W. Zandvliet, D. Lohse, H. Riegler, Nonintrusive Optical Visualization of Surface Nanobubbles, Phys. Rev. Lett. 109 (2012) 066102. doi: 10.1103/PhysRevLett.109.066102.
   Google Scholar
• A. Albanese, P.S. Tang, W.C.W. Chan, The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems, Annu. Rev. Biomed. Eng. 14 (2012) 1–16. doi: 10.1146/annurev-bioeng-071811-150124.
   Google Scholar
• C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles, Biomaterials 31 (2010) 3657–3666. doi: 10.1016/j.biomaterials.2010.01.065.
   Google Scholar
• H. Soo Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, J.V. Frangioni, Renal clearance of quantum dots, Nat. Biotechnol. 25 (2007) 1165–1170. doi: 10.1038/nbt1340.
   Google Scholar
• K. Xiao, Y. Li, J. Luo, J.S. Lee, W. Xiao, A.M. Gonik, R.G. Agarwal, K.S. Lam, The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles, Biomaterials 32 (2011) 3435–3446. doi: 10.1016/j.biomaterials.2011.01.021.
   Google Scholar
• S. Hirn, M. Semmler-Behnke, C. Schleh, A. Wenk, J. Lipka, M. Schäffler, S. Takenaka, W. Möller, G. Schmid, U. Simon, W.G. Kreyling, Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration, Eur. J. Pharm. Biopharm. 77 (2011) 407–416. doi: 10.1016/j.ejpb.2010.12.029.
   Google Scholar
• S. Azzi, J.K. Hebda, J. Gavard, Vascular Permeability and Drug Delivery in Cancers, Front. Oncol. 3 (2013). doi: 10.3389/fonc.2013.00211.
   Google Scholar
• B. Lahooti, R.G. Akwii, F.T. Zahra, M.S. Sajib, M. Lamprou, A. Alobaida, M.S. Lionakis, G. Mattheolabakis, C.M. Mikelis, Targeting endothelial permeability in the EPR effect, J. Controlled Release 361 (2023) 212–235. doi: 10.1016/j.jconrel.2023.07.039.
   Google Scholar
• R. Sun, J. Xiang, Q. Zhou, Y. Piao, J. Tang, S. Shao, Z. Zhou, Y.H. Bae, Y. Shen, The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives, Adv. Drug Deliv. Rev. 191 (2022) 114614. doi: 10.1016/j.addr.2022.114614.
   Google Scholar
• M.S. Chauhan, S.R. Anand, In vitro maturation and fertilization of goat oocytes, Indian J. Exp. Biol. 29 (1991) 105–110.
   Google Scholar
• L.E. Gerlowski, R.K. Jain, Microvascular permeability of normal and neoplastic tissues, Microvasc. Res. 31 (1986) 288–305. doi: 10.1016/0026-2862.(86)90018-X.
   Google Scholar
• F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res. 55 (1995) 3752–3756.
   Google Scholar
• K. Igarashi, H. Cabral, T. Hong, Y. Anraku, F. Mpekris, T. Stylianopoulos, T. Khan, A. Matsumoto, K. Kataoka, Y. Matsumoto, T. Yamasoba, Vascular Bursts Act as a Versatile Tumor Vessel Permeation Route for Blood‐Borne Particles and Cells, Small 17 (2021) 2103751. doi: 10.1002/smll.202103751.
   Google Scholar
• H. Salavati, C. Debbaut, P. Pullens, W. Ceelen, Interstitial fluid pressure as an emerging biomarker in solid tumors, Biochim. Biophys. Acta BBA - Rev. Cancer 1877 (2022) 188792. doi: 10.1016/j.bbcan.2022.188792.
   Google Scholar
• T. Zhang, Y. Jia, Y. Yu, B. Zhang, F. Xu, H. Guo, Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy, Adv. Drug Deliv. Rev. 186 (2022) 114319. doi: 10.1016/j.addr.2022.114319.
   Google Scholar
• S.B. Keller, M.A. Averkiou, The Role of Ultrasound in Modulating Interstitial Fluid Pressure in Solid Tumors for Improved Drug Delivery, Bioconjug. Chem. 33 (2022) 1049–1056. doi: 10.1021/acs.bioconjchem.1c00422.
   Google Scholar
• A. Mohammadabadi, R.N. Huynh, A.S. Wadajkar, R.G. Lapidus, A.J. Kim, C.B. Raub, V. Frenkel, Pulsed focused ultrasound lowers interstitial fluid pressure and increases nanoparticle delivery and penetration in head and neck squamous cell carcinoma xenograft tumors, Phys. Med. Biol. 65 (2020) 125017. doi: 10.1088/1361-6560/ab9705.
   Google Scholar
• B. Mishra, B.B. Patel, S. Tiwari, Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery, Nanomedicine Nanotechnol. Biol. Med. 6 (2010) 9–24. doi: 10.1016/j.nano.2009.04.008.
   Google Scholar
• S. Yan, L. Yang, L. Lu, Q. Guo, X. Hu, Y. Yuan, Y. Li, M. Wu, J. Zhang, Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems, Expert Opin. Drug Metab. Toxicol. 14 (2018) 951–960. doi: 10.1080/17425255.2018.1505863.
   Google Scholar
• F.U. Din, W. Aman, I. Ullah, O.S. Qureshi, O. Mustapha, S. Shafique, A. Zeb, Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, Int. J. Nanomedicine Volume 12 (2017) 7291–7309. doi: 10.2147/IJN.S146315.
   Google Scholar
• A.P.G. Walsh, H.N. Gordon, K. Peter, X. Wang, Ultrasonic particles: An approach for targeted gene delivery, Adv. Drug Deliv. Rev. 179 (2021) 113998. doi: 10.1016/j.addr.2021.113998.
   Google Scholar
• Y. Nakamura, A. Mochida, P.L. Choyke, H. Kobayashi, Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?, Bioconjug. Chem. 27 (2016) 2225–2238. doi: 10.1021/acs.bioconjchem.6b00437.
   Google Scholar
• C. Chen, M. Sun, J. Wang, L. Su, J. Lin, X. Yan, Active cargo loading into extracellular vesicles: Highlights the heterogeneous encapsulation behaviour, J. Extracell. Vesicles 10 (2021) e12163. doi: 10.1002/jev2.12163.
   Google Scholar